Related Experiment Video

Updated: Sep 26, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Pharmacologic prevention of coronary artery disease. What do clinical trials show?

R V Milani1, C J Lavie

  • 1Department of Internal Medicine, Ochsner Medical Institutions, New Orleans, LA 70121, USA. RMilani@ochsner.org

Postgraduate Medicine
|February 1, 1996
PubMed

Insights

Aggressive pharmacologic therapy may halt or reverse atherosclerotic heart disease, significantly reducing cardiac events. This review examines key studies on lipid-lowering agents, aspirin, estrogen, and calcium antagonists.

Area of Science:

  • Cardiology
  • Pharmacology
  • Preventive Medicine

Background:

  • Atherosclerotic heart disease is a major cause of morbidity and mortality.
  • Plaque regression, even if small, is associated with reduced clinical cardiac events.
  • Pharmacologic interventions are being investigated for their potential to modify disease progression.

Purpose of the Study:

  • To evaluate the efficacy of aggressive pharmacologic therapy in halting or reversing atherosclerotic heart disease.
  • To review the impact of various drug classes on plaque regression and clinical outcomes.
  • To synthesize findings from key studies on lipid-lowering agents, aspirin, estrogen replacement, and calcium antagonists.

Main Methods:

  • Systematic review and analysis of existing clinical studies.
  • Examination of data on lipid-lowering agents (e.g., statins).
  • Evaluation of studies on low-dose aspirin, estrogen replacement therapy, and calcium antagonists.

Main Results:

  • Studies indicate that lipid-lowering agents can induce plaque regression.
  • Low-dose aspirin shows potential in reducing cardiac events.
  • Estrogen replacement and calcium antagonists have varying effects on atherosclerotic progression and outcomes.

Conclusions:

  • Aggressive pharmacologic therapy holds promise for managing atherosclerotic heart disease.
  • Modest plaque regression achieved through medication may lead to significant clinical benefits.
  • Further research is warranted to optimize therapeutic strategies for cardiovascular disease prevention and treatment.

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...